Elevated fibrinogen levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 3, 2013, Pages 286-293

  Klovaite, Jolanta ^a,b   Nordestgaard, Borge G ^a,b,c   Tybjrg Hansen, Anne ^a,b,c,d   Benn, Marianne ^a,b  

^a Copenhagen University Hospital ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Fibrinogen; General population; Hemostasis; Venous thromboembolism

Indexed keywords

FIBRINOGEN;

ADULT; AGED; ALLELE; ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

AGED; BIOLOGICAL MARKERS; DENMARK; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84873379034     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201207-1232OC     Document Type: Article

References (29)

1. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. a case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994;71:719-722.
2. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of Factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999;81:680-683.
3. van Hylckama VA, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 2003;1:2677-2678.
4. Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM 2003;96:711-729.
5. Klovaite J, Benn M, Yazdanyar S, Nordestgaard BG. High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population. J Thromb Haemost 2011;9:49-56.
6. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J InternMed 2011; 270:65-75.
7. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG, Factor V. Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004;140:330-337.
8. Nielsen SF, Nordestgaard BG, Bojesen SE. Associations between first and second primary cancers: a population-based study. CMAJ 2012; 184:E57-E69.
9. Bay-Nielsen H. Classification of surgical procedures, 1st ed. Copenhagen, Denmark: Nordic Medico Statistical Committee (NOMESCO); 1996.
10. Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007;5:116-124.
11. Blomback B. Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res 1996;83:1-75.
12. Glover CJ, McIntire LV, Brown CH III, Natelson EA. Rheological properties of fibrin clots. Effects of fibrinogen concentration, factor XIII deficiency, and factor XIII inhibition. J Lab Clin Med 1975;86: 644-656.
13. Theusinger OM, Baulig W, Asmis LM, Seifert B, Spahn DR. In vitro factor XIII supplementation increases clot firmness in rotation thromboelastometry (ROTEM). Thromb Haemost 2010;104:385-391.
14. Kucher N, Schroeder V, Kohler HP. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. Thromb Haemost 2003;90:434-438.
15. Bang NU, Freiman AH, Cliffton EE. Effect of increased fibrinogen concentration on the lysis of in vivo thrombi. Circ Res 1960;8:419-422.
16. Doutremepuich F, Aguejouf O, Belougne-Malfatti E, Doutremepuich C. Fibrinogen as a factor of thrombosis: experimental study. Thromb Res 1998;90:57-64.
17. Reed T, Tracy RP, Fabsitz RR. Minimal genetic influences on plasma fibrinogen level in adult males in the NHLBI twin study. Clin Genet 1994;45:71-77.
18. Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987;2:988-991.
19. Verschuur M, de Jong M, Felida L, de Maat MP, Vos HL. A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent -148C/T polymorphism. J Biol Chem 2005;280: 16763-16771.
20. de Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996;121:185-191.
21. Humphries SE, Panahloo A, Montgomery HE, Green F, Yudkin J. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost 1997;78:457-461.
22. Folsom AR. Epidemiology of fibrinogen. Eur Heart J 1995;16:21-23.
23. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G-455→ A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997;99:3034-3039.
24. Jacquemin B, Antoniades C, Nyberg F, Plana E, Muller M, Greven S, Salomaa V, Sunyer J, Bellander T, Chalamandaris AG, et al. Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol 2008;52:941-952.
25. Smith GD, Harbord R, Milton J, Ebrahim S, Sterne JA. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005;25:2228-2233.
26. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352.
27. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstrom T, Berkowitz SD, Nystrom P, Thorsen M, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-689.
28. van Langevelde K, Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC. Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. Blood 2012;120:933-946.
29. Cook DG, Cappuccio FP, Atkinson RW, Wicks PD, Chitolie A, Nakandakare ER, Sagnella GA, Humphries SE. Ethnic differences in fibrinogen levels: the role of environmental factors and the betafibrinogen gene. Am J Epidemiol 2001;153:799-806.